Selected article for: "chronic inflammation and immune dysfunction"
Author: Frasca, Daniela; Reidy, Lisa; Cray, Carolyn; Diaz, Alain; Romero, Maria; Kahl, Kristin; Blomberg, Bonnie B.
Title: Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients
  • Cord-id: 9ub5p6fy
  • Document date: 2021_3_24
    • ID: 9ub5p6fy
    Snippet: SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-2), cause of COVID-19 (Coronavirus Disease of 2019), represents a significant risk to people living with pre-existing conditions associated with exacerbated inflammatory responses and consequent dysfunctional immunity. In this paper, we have evaluated the influence of obesity, a condition associated with chronic systemic inflammation, on the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. Our hypothesis
    Document: SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-2), cause of COVID-19 (Coronavirus Disease of 2019), represents a significant risk to people living with pre-existing conditions associated with exacerbated inflammatory responses and consequent dysfunctional immunity. In this paper, we have evaluated the influence of obesity, a condition associated with chronic systemic inflammation, on the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. Our hypothesis is that obesity is associated with reduced amounts of specific IgG antibodies. Results have confirmed our hypothesis and have shown that SARS-CoV-2 IgG antibodies are negatively associated with Body Mass Index (BMI) in COVID-19 obese patients, as expected based on the known influence of obesity on humoral immunity. Antibodies in COVID-19 obese patients are also negatively associated with serum levels of pro-inflammatory and metabolic markers of inflammaging and pulmonary inflammation, such as SAA (serum amyloid A protein), CRP (C-reactive protein), and ferritin, but positively associated with NEFA (nonesterified fatty acids). These results altogether could help to identify an inflammatory signature with strong predictive value for immune dysfunction. Inflammatory markers identified may subsequently be targeted to improve humoral immunity in individuals with obesity and in individuals with other chronic inflammatory conditions.

    Search related documents:
    Co phrase search for related documents
    • abdominal area and adipose tissue: 1
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute respiratory syndrome corona: 1, 2, 3
    • absence presence and additional marker: 1
    • absence presence and adipose tissue: 1, 2, 3, 4, 5
    • absence presence and local inflammation: 1, 2
    • absence presence and low amount: 1
    • absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory and additional marker: 1, 2
    • acute respiratory and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and locked spike conformation: 1, 2
    • acute respiratory and low amount: 1, 2, 3, 4
    • acute respiratory and low grade systemic inflammation: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome corona and lung disease: 1, 2, 3, 4
    • adipose tissue and local inflammation: 1, 2, 3, 4, 5, 6
    • adipose tissue and low grade systemic inflammation: 1, 2, 3
    • adipose tissue and lung disease: 1, 2, 3, 4